Wells Fargo & Company MN Purchases 4,886 Shares of Enanta Pharmaceuticals Inc (ENTA)
Wells Fargo & Company MN grew its position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 36.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,197 shares of the biotechnology company’s stock after purchasing an additional 4,886 shares during the quarter. Wells Fargo & Company MN’s holdings in Enanta Pharmaceuticals were worth $852,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Hartland & Co. LLC acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at about $237,000. Municipal Employees Retirement System of Michigan raised its position in shares of Enanta Pharmaceuticals by 63.7% during the third quarter. Municipal Employees Retirement System of Michigan now owns 5,370 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 2,090 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Enanta Pharmaceuticals by 30.0% during the third quarter. SG Americas Securities LLC now owns 5,662 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 1,308 shares during the last quarter. Crossmark Global Holdings Inc. bought a new position in shares of Enanta Pharmaceuticals during the third quarter worth about $289,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Enanta Pharmaceuticals by 69.1% during the third quarter. BNP Paribas Arbitrage SA now owns 7,456 shares of the biotechnology company’s stock worth $349,000 after acquiring an additional 3,047 shares during the last quarter. 66.89% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently issued reports on ENTA. Royal Bank of Canada downgraded Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 price objective for the company. in a research report on Tuesday, January 2nd. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. JMP Securities raised their price objective on Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Finally, TheStreet upgraded Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $45.25.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The company had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same quarter last year, the business earned ($0.09) earnings per share. Enanta Pharmaceuticals’s revenue was up 491.3% compared to the same quarter last year. equities analysts forecast that Enanta Pharmaceuticals Inc will post -1.57 EPS for the current fiscal year.
WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/wells-fargo-company-mn-purchases-4886-shares-of-enanta-pharmaceuticals-inc-enta/1827556.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.